In a phase I/early II trial, patients with stage III or IV malignancies, including three with bladder cancer, all MAGE-3 positive, were randomized to three different escalation dose levels of a recombinant MAGE-3 vaccine, associated with fixed doses of an immunological adjuvant, in order to further improve its immunogenicity. The gene discussed is MAGEA3; the disease is urinary bladder cancer.